Story
Nov 1, 2026
Anthropic’s IPO asks investors to fund miracles before its compute bill comes due
Anthropic’s supporters see a fast-growing enterprise AI company whose expanding role in coding and science can unlock far larger customer budgets. Skeptics see the same filing as a warning that immense compute obligations, decelerating growth and limited investor control leave little room for a stumble.
Anthropic’s public S-1, filed ahead of a prospective blockbuster IPO, presents an unusual bargain: investors are invited to back both a commercial software business and a stated mission to steer advanced AI safely. Its founders tell would-be shareholders not to view a purchase “in purely transactional terms,” casting the company’s work as an opportunity to “bring forth an age of miracles.”1
The financial case initially looks formidable. Anthropic reported $16.3 billion in first-half 2026 revenue, while customers already using its products generated roughly nine times as much revenue as a year earlier. More than half of the Fortune 500 reportedly includes customers spending at least $100,000 annually, suggesting Claude remains a tiny line item inside vast corporate budgets rather than a fully exhausted market.2
That growth story is increasingly tied to life sciences. Anthropic launched Claude Science in beta in June, opened a molecular-biology lab, acquired Coefficient Bio for $400 million in stock in April and has sought to position its models in drug discovery. Nine of the 10 largest pharmaceutical companies in the Fortune 500 spent at least $100,000 with it over a recent year, according to the filing.3 The promise is compelling; the commercial proof remains incomplete, with no AI-designed drug yet approved by the FDA.
Then comes the bill. Analysts parsing the filing point to hundreds of billions of dollars in compute and infrastructure commitments, with one assessment putting the minimum near $850 billion over two decades. “Growth is not optional for this company,” PitchBook analyst Harrison Rolfes wrote. “The contracts assume it.”4
The timing has sharpened the tension. Revenue growth reportedly slowed from about 144% quarter-on-quarter in the second quarter to roughly 47% in the third, while investors still lack a clear view of the marginal cost of future revenue.5 Anthropic’s public-benefit structure adds another wrinkle: its seven co-founders retain 50.1% voting power through a special Class F share.
For believers, lower compute costs and deeper adoption can keep the flywheel spinning. For doubters, the IPO is a wager that demand, scientific breakthroughs and model progress will arrive fast enough to outrun commitments already locked in.